TOXICITY AND EFFICACY OF TYROSINE KINASE INHIBITORS IN COMBINATION WITH CHEMOTHERAPY IN PATIENT WITH RESISTANT Ph-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (CASE REPORT AND LITERATURE REVIEW)
A wide range of toxic complications of BCR-ABL tyrosine kinase inhibitors therapy due to non-targeted inhibition of other protein kinases. This is of particular importance in the treatment of patients with Ph-positive lymphoblastic leukemia, who receive, in addition to tyrosine kinase inhibitors, cy...
Main Authors: | K. I. Zarubina, E. N. Parovichnikova, O. A. Gavrilina, A. N. Sokolov, V. V. Troitskaya, L. A. Kuzmina, V. E. Mamonov, G. M. Galstyan, V. G. Savchenko |
---|---|
Format: | Article |
Language: | Russian |
Published: |
ABV-press
2017-10-01
|
Series: | Onkogematologiâ |
Subjects: | |
Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/257 |
Similar Items
-
BCR-ABL tyrosine kinase inhibitor (TKI)-induced nephropathy: An under-recognized phenomenon
by: Michele Stanchina, et al.
Published: (2020-01-01) -
Axitinib in Ponatinib-Resistant B-Cell Acute Lymphoblastic Leukemia Harboring a T315L Mutation
by: Valentina Giudice, et al.
Published: (2020-12-01) -
Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid Leukemia
by: Marialuisa Polillo, et al.
Published: (2015-09-01) -
Extending the duration of response in chronic myelogenous leukemia: targeted therapy with sequential tyrosine kinase inhibitors
by: Michael G. Martin, et al.
Published: (2011-12-01) -
Tyrosine Kinase Inhibitor Sequencing in Patients with Chronic Myeloid Leukemia
by: Mario Tiribelli, et al.
Published: (2019-08-01)